| ABIVAX SA EO -,01 |
| Frankreich |
| Gesundheit |
| FR0012333284 / A14UQC |
| 2X1 (Frankfurt) |
| FRA:2X1, ETR:2X1, 2X1:GR |
| - |
| https://www.abivax.com/ |
|
Abivax SA is a clinical-stage biotechnology company developing innovative therapies for chronic inflammatory diseases. Its research platform focuses on harnessing the body’s natural regulatory mechanisms to help restore and stabilize immune respons..
>Volltext.. |
| 6899.02 Mio. EUR |
| 6497.32 Mio. EUR |
| - |
| -302.21 Mio. EUR |
| -409.04 Mio. EUR |
| -5.34 EUR |
| 1.24 Mio. EUR |
| 395.55 Mio. EUR |
| -197.5 Mio. EUR |
| 5.61 |
| - |
| -126.13% |
| - |
| - |
| - |
| - |
| ABIVAX |
| 24.10.26 |
|